类风湿关节炎中对抗肿瘤坏死因子药物的差异耐药性
Differential drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
作者信息
Sidiropoulos P I, Boumpas D T
出版信息
Ann Rheum Dis. 2006 Jun;65(6):701-3. doi: 10.1136/ard.2005.049890.
Abstract
A significant number of patients receiving infliximab require dosing adjustments while some patients may indeed develop drug resistance
摘要
相当数量接受英夫利昔单抗治疗的患者需要调整剂量，而一些患者可能确实会产生耐药性。
相似文献
1
Differential drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.类风湿关节炎中对抗肿瘤坏死因子药物的差异耐药性
Ann Rheum Dis. 2006 Jun;65(6):701-3. doi: 10.1136/ard.2005.049890.
2
[Should we be afraid of the anti-TNFalpha drugs in 2008?].2008年我们应该害怕抗肿瘤坏死因子α药物吗？
Rev Med Interne. 2008 Dec;29(12):971-4. doi: 10.1016/j.revmed.2008.04.022. Epub 2008 Jun 20.
3
[Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].[类风湿关节炎患者对传统治疗难治时使用抗肿瘤坏死因子α制剂的情况]
Med Clin (Barc). 2010 May 22;134(15):684-5. doi: 10.1016/j.medcli.2009.12.003. Epub 2010 Feb 21.
4
[Anti-TNF therapy in rheumatoid arthritis].[类风湿关节炎中的抗TNF治疗]
Nihon Rinsho Meneki Gakkai Kaishi. 2004 Feb;27(1):7-15. doi: 10.2177/jsci.27.7.
5
Which TNF inhibitor for rheumatoid arthritis?哪种肿瘤坏死因子抑制剂用于治疗类风湿性关节炎？
Med Lett Drugs Ther. 2010 May 17;52(1338):38-9.
6
Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register).肿瘤坏死因子抑制剂的药物留存率：来自意大利国家登记处（GISEA登记处）的2003 - 2004年数据。
Ann Rheum Dis. 2014 Jun;73(6):e31. doi: 10.1136/annrheumdis-2013-205011. Epub 2013 Dec 24.
7
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.阿达木单抗、依那西普和英夫利昔单抗治疗成人类风湿关节炎有效性的系统评价及其成本效益的经济学评估。
Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. doi: 10.3310/hta10420.
8
Efficacy of treatment intensification with adalimumab, etanercept and infliximab in rheumatoid arthritis: a systematic review of cohort studies with focus on dose.阿达木单抗、依那西普和英夫利昔单抗强化治疗类风湿关节炎的疗效：侧重于剂量的队列研究系统评价。
Semin Arthritis Rheum. 2013 Oct;43(2):144-51. doi: 10.1016/j.semarthrit.2013.01.007. Epub 2013 Jul 6.
9
Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.在管理式医疗人群中，类风湿关节炎肿瘤坏死因子拮抗剂疗法的年度用药成本及剂量增加率的差异。
Clin Ther. 2009 Apr;31(4):825-35. doi: 10.1016/j.clinthera.2009.04.002.
10
TNF inhibitors: a new age in rheumatoid arthritis treatment.肿瘤坏死因子抑制剂：类风湿关节炎治疗的新时代。
Am J Nurs. 2004 Feb;104(2):60-8; quiz 68-9. doi: 10.1097/00000446-200402000-00023.
引用本文的文献
1
Programmatically activated DNA hydrogel microcapsules for precision therapy in inflammatory bowel disease.用于炎症性肠病精准治疗的程序化激活DNA水凝胶微胶囊
Theranostics. 2025 May 8;15(13):6203-6220. doi: 10.7150/thno.111583. eCollection 2025.
2
TIPE2 inhibits melanoma progression through MEK/ERK signaling.TIPE2 通过 MEK/ERK 信号抑制黑色素瘤进展。
Sci Rep. 2024 Nov 12;14(1):27736. doi: 10.1038/s41598-024-76794-z.
3
Inference of an Integrative, Executable Network for Rheumatoid Arthritis Combining Data-Driven Machine Learning Approaches and a State-of-the-Art Mechanistic Disease Map.结合数据驱动的机器学习方法与先进的机制性疾病图谱，推断类风湿性关节炎的综合可执行网络。
J Pers Med. 2021 Aug 12;11(8):785. doi: 10.3390/jpm11080785.
4
Psoriasis and Gut Microbiome-Current State of Art.银屑病与肠道微生物组——现状。
Int J Mol Sci. 2021 Apr 26;22(9):4529. doi: 10.3390/ijms22094529.
5
Oncogenic Role of Tumor Necrosis Factor α-Induced Protein 8 (TNFAIP8).肿瘤坏死因子α诱导蛋白 8（TNFAIP8）的致癌作用。
Cells. 2018 Dec 24;8(1):9. doi: 10.3390/cells8010009.
6
Genetic and pharmacological validation of TAK1 inhibition in macrophages as a therapeutic strategy to effectively inhibit TNF secretion.在巨噬细胞中抑制 TAK1 的遗传和药理学验证作为一种有效的抑制 TNF 分泌的治疗策略。
Sci Rep. 2018 Nov 19;8(1):17058. doi: 10.1038/s41598-018-35189-7.
7
Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study.依那西普、阿达木单抗和英夫利昔单抗之间的剂量递增与联合治疗强化：CADURA研究
Open Rheumatol J. 2017 Oct 24;11:123-135. doi: 10.2174/1874312901711010123. eCollection 2017.
8
The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients.对首次抗TNF治疗的免疫原性决定了脊柱关节炎患者换用第二种抗TNF治疗的结果。
Arthritis Res Ther. 2013 Jul 26;15(4):R79. doi: 10.1186/ar4258.
9
TNFR1 signaling kinetics: spatiotemporal control of three phases of IKK activation by posttranslational modification.TNFR1 信号转导动力学：通过翻译后修饰对 IKK 激活的三个阶段进行时空控制。
Cell Signal. 2013 Aug;25(8):1654-64. doi: 10.1016/j.cellsig.2013.04.005. Epub 2013 Apr 21.
10
Randomised controlled trial examining the effect of exercise in people with rheumatoid arthritis taking anti-TNFα therapy medication.随机对照试验研究了在接受抗 TNF-α 治疗药物的类风湿关节炎患者中运动的效果。
BMC Musculoskelet Disord. 2011 Jan 13;12:11. doi: 10.1186/1471-2474-12-11.
本文引用的文献
1
The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden.LUNDEX，一种临床实践中药物疗效的新指标：瑞典南部类风湿关节炎患者使用英夫利昔单抗和依那西普治疗的五年观察性研究结果
Arthritis Rheum. 2006 Feb;54(2):600-6. doi: 10.1002/art.21570.
2
Acquired resistance to chloroquine in human CEM T cells is mediated by multidrug resistance-associated protein 1 and provokes high levels of cross-resistance to glucocorticoids.人CEM T细胞对氯喹的获得性耐药由多药耐药相关蛋白1介导，并引发对糖皮质激素的高水平交叉耐药。
Arthritis Rheum. 2006 Feb;54(2):557-68. doi: 10.1002/art.21569.
3
4
The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study.抗肿瘤坏死因子疗法在预防类风湿关节炎患者影像学关节损害进展方面的有效性：一项基于人群的研究。
Arthritis Rheum. 2006 Jan;54(1):54-9. doi: 10.1002/art.21491.
5
Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.类风湿关节炎中对抗肿瘤坏死因子药物获得性耐药差异的证据。
Ann Rheum Dis. 2006 Jun;65(6):746-52. doi: 10.1136/ard.2005.045062. Epub 2005 Dec 8.
6
Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study.阿达木单抗联合甲氨蝶呤治疗类风湿关节炎患者的长期疗效及安全性：ARMADA 4年扩展研究
Ann Rheum Dis. 2006 Jun;65(6):753-9. doi: 10.1136/ard.2005.044404. Epub 2005 Nov 24.
7
Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles.肿瘤坏死因子抑制剂：不同免疫原性特征的临床意义。
Semin Arthritis Rheum. 2005 Apr;34(5 Suppl1):19-22. doi: 10.1016/j.semarthrit.2005.01.005.
8
Clinical pharmacokinetics of TNF antagonists: how do they differ?肿瘤坏死因子拮抗剂的临床药代动力学：它们有何不同？
Semin Arthritis Rheum. 2005 Apr;34(5 Suppl1):12-8. doi: 10.1016/j.semarthrit.2005.01.004.
9
Treatment continuation in patients receiving biological agents or conventional DMARD therapy.接受生物制剂或传统改善病情抗风湿药治疗的患者的治疗延续情况。
Ann Rheum Dis. 2005 Sep;64(9):1274-9. doi: 10.1136/ard.2004.031476. Epub 2005 Feb 11.
10
Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis.英夫利昔单抗剂量与临床状况：针对1642例类风湿关节炎患者的两项研究结果
J Rheumatol. 2004 Aug;31(8):1538-45.
Zotero 插件